Skip to main content

Table 3 Adverse events (CTCAE version 3.0)

From: Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study

Adverse events Grade 1–2 n (%) Grade 3–4 n (%)
Conjunctiva 1 (5.3%) 0
Pneumonitis/pulmonary infiltrates 1 (5.3%) 0
Neuropathy 1 (5.3%) 0
Skin cancer (basal cell carcinoma) 0 1 (5.3%)
Lymphoma 0 1 (5.3%)
Anemia 0 0
Thrombocytopenia 1 (5.3%) 0
Leucopenia 0 0
Hypercholesterolemia/hyperglycemia 0 0
Headache 11 (57.9%) 0
Arterial hypertension 1 (5.3%) 0
Diarrhea 7 (36.9%) 0
Nausea/vomiting 5 (26.4%) 0
Mucositis/stomatitis 7 (36.9%) 2 (10.6%)
Abnormal liver function tests 0 0
Rash 7 (36.9%) 0
Arthralgia 1 (5.3%) 0
Flu-like syndrome 6 (31.6%) 0
Fatigue 9 (47.4%) 0
Wound healing 2 (10.6%) 0
Weight loss 3 (15.8%) 0
Insomnia 4 (21.1%) 0